Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors. - Wikidata - awgldk - TriplyDB

Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors.

Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors.

http://www.wikidata.org/entity/Q37383940

about

Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patients Drug-Drug Interactions Based on Pharmacogenetic Profile between Highly Active Antiretroviral Therapy and Antiblastic Chemotherapy in Cancer Patients with HIV Infection Functional impact of ABCB1 variants on interactions between P-glycoprotein and methadone Metabolic and kidney disorders correlate with high atazanavir concentrations in HIV-infected patients: is it time to revise atazanavir dosages?New treatment strategies for HIV-positive cancer patients undergoing antiblastic chemotherapy.Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202.Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202.Atazanavir metabolism according to CYP3A5 status: an in vitro-in vivo assessment.Atazanavir/ritonavir-based combination antiretroviral therapy for treatment of HIV-1 infection in adults.Population pharmacokinetics of atazanavir/ritonavir in HIV-1-infected children and adolescents.Relationship Between Genital Drug Concentrations and Cervical Cellular Immune Activation and Reconstitution in HIV-1-Infected Women on a Raltegravir Versus a Boosted Atazanavir Regimen.The clinical application of UGT1A1 pharmacogenetic testing: gene-environment interactions Discordant associations between SLCO1B1 521T→C and plasma levels of ritonavir-boosted protease inhibitors in AIDS clinical trials group study A5146.Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342).Clinical pharmacokinetics of antiretroviral drugs in older persons.Effect of the African Traditional Medicine, Sutherlandia frutescens, on the Bioavailability of the Antiretroviral Protease Inhibitor, Atazanavir.Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients.Antiretroviral drug toxicity in relation to pharmacokinetics, metabolic profile and pharmacogenetics.The effect of ABCB1 genetic variants on chemotherapy response in HIV and cancer treatment.Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding.Effect of the UGT1A1*28 allele on unconjugated hyperbilirubinemia in HIV-positive patients receiving Atazanavir: a systematic review.Population pharmacokinetic modelling of the changes in atazanavir plasma clearance caused by ritonavir plasma concentrations in HIV-1 infected patients.Pharmacogenetic Analysis of the Model-Based Pharmacokinetics of Five Anti-HIV Drugs: How Does This Influence the Effect of Aging?Pharmacokinetics and pharmacodynamics of atazanavir-containing antiretroviral regimens, with or without ritonavir, in patients who are HIV-positive and treatment-naïve.A Genome-Wide Association Study Identifies a Candidate Gene Associated With Atazanavir Exposure Measured in Hair.PharmGKB summary: atazanavir pathway, pharmacokinetics/pharmacodynamics

P2860

Q24602072-46672347-9784-40E4-A101-3AB428ADEC11 Q26749811-5059AC53-3B7F-4D62-86CE-8B85E4B48F81 Q28488223-9FDE3019-3873-4E71-8614-B5A1E7FBC89D Q28546430-DFA1F42F-0529-4D44-A568-DB2A46B8E5C1 Q30244166-96B39910-153D-4011-AB86-5189267C7F04 Q33760652-BA1BCD53-6814-41CF-A5DB-F8D84BF1721C Q34495619-553CC5A7-E63E-4F4B-98CA-6F4924766D02 Q34702608-ADB44DAB-E5AA-458F-A4C7-D94257D01964 Q35079510-C0509776-6C67-489F-AC8F-E618F5575485 Q35629777-CC10FCB9-65E5-461A-9EB7-D055D9BDD5BC Q36078470-5A05F85B-3363-4CD4-BFD6-DB507FE819BC Q36475104-701507CE-0483-4B7F-9DB3-C82E9FD6CD3C Q36701911-CE824157-FD5F-45B2-92E8-D9CF6A558B4C Q36901492-B48B3E5E-A333-4D17-9DD8-736BAE7800E3 Q36905884-7913E7A1-CF69-4008-8B41-8F866880E1E1 Q37422412-AD67D903-A664-4611-B86B-5FB37CCDE6FA Q37611687-B6C35F46-8C5D-4530-905C-27A6698CF14B Q37866298-F77E3AC1-44F5-4202-8861-8B387331B6C5 Q37946959-EFF3F193-F738-4177-9A16-FDF32C52E7E0 Q38051400-CD5A687E-3F6F-41D9-A350-27517B718F20 Q38095232-9580DFEA-4B85-4BBA-A03C-B63993B60621 Q40603398-A662356E-C021-41CE-A709-338378B3972D Q44877659-2E8BBDA8-D6DA-4C62-9AC4-CC405500B4F2 Q46825226-B0989D2B-79D2-45B4-B158-14715DDBF95B Q50120171-2D7B5638-29E8-4DE6-ABE6-97226A044FDD Q57403878-314BC400-8298-417C-B0FB-4C7859C5EE30

P2860

Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors.

http://www.wikidata.org/entity/Q37383940

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 26 August 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Atazanavir pharmacokinetics in ...... ressors versus non-expressors.

@en

Atazanavir pharmacokinetics in ...... ressors versus non-expressors.

@nl

type

label

Atazanavir pharmacokinetics in ...... ressors versus non-expressors.

@en

Atazanavir pharmacokinetics in ...... ressors versus non-expressors.

@nl

prefLabel

Atazanavir pharmacokinetics in ...... ressors versus non-expressors.

@en

Atazanavir pharmacokinetics in ...... ressors versus non-expressors.

@nl

P1433

Q37383940-D56A0EAF-3076-4D2D-ABC5-BFC8F8A71F79

P1476

Q37383940-A31A5F76-C439-4270-9C8B-D8FD869EA209

P2093

Q37383940-1BB3BC31-000F-42C8-9E65-E59E144BEDF3

Q37383940-1F923CFB-03C4-4845-916C-0FBE1F8FB7EA

Q37383940-2DB7A19D-20D0-4BFA-87EB-83EBC440EEF4

Q37383940-49C96923-0320-49C0-9131-6F843893323E

Q37383940-5C5AA684-F495-4CC5-9806-51FDD550C6B3

Q37383940-5F07A3D2-33E2-4D7C-B6AF-5414BCE7FEC5

Q37383940-A17EDEAE-3E49-463C-A432-433E84749E01

Q37383940-C3A03287-34FE-4FCE-A073-E2BFE1E7DBCD

Q37383940-EB4431B6-BC7A-4B6B-BA45-38F3A974B7E8

P2860

Q37383940-01C9E899-2F88-4F18-BA41-C845F9FE19DC

Q37383940-03D8714D-AAC2-4762-A355-53173F0C49F5

Q37383940-059F6054-B4E6-421C-A0E8-02CF0E6B3927

Q37383940-0A8BFF1C-A422-4F81-814D-E9A83E559989

Q37383940-28A9B268-EE21-4A7B-BEDF-E40A3D61413B

Q37383940-2ECD4493-031C-41A4-836F-567A2BDE2B40

Q37383940-39ACB03D-605B-4F03-A0E6-9FC45420963E

Q37383940-3A846C87-44FF-4A00-B94F-6A09EE6F6B9B

Q37383940-3DF7D185-876D-4A83-BB61-F422776FB6DC

Q37383940-3EF0776C-C304-43A9-9AF8-0152954E47EE

P304

Q37383940-4A04FD9F-FB4B-48B5-AA1D-C57B839AE558

P31

Q37383940-719DC4A5-9471-4F72-A698-BA0506C4A34B

P356

Q37383940-AAD43EEC-CA53-4273-9286-82D39FBE27BA

P407

Q37383940-892D5906-B20A-4EE4-A78B-A6ACB70C8BDF

P433

Q37383940-39A0D916-3B42-4967-B413-0BEE0D6A41A9

P478

Q37383940-F7AC8574-FED2-403E-A53B-A6B735DC7684

P577

Q37383940-D253011E-7E8A-4FEA-AEC4-C577E995AD91

P5875

Q37383940-EEA9A453-ED9C-464E-A7AA-55A9E7DBB5F3

P698

Q37383940-0AA7F9DD-9235-4978-B30F-40A18DBD5F6C

P932

Q37383940-F4FA26F6-D7FF-44F2-8DC2-921CFD03AE59

P356

P1433

Journal of Antimicrobial Chemotherapy

P1476

Atazanavir pharmacokinetics in ...... ressors versus non-expressors.

@en

P2093

Christina L Aquilante

http://www.w3.org/2001/XMLSchema#string

Edward M Gardner

http://www.w3.org/2001/XMLSchema#string

Jia-Hua Zheng

http://www.w3.org/2001/XMLSchema#string

Julie Predhomme

http://www.w3.org/2001/XMLSchema#string

Lane R Bushman

http://www.w3.org/2001/XMLSchema#string

Michelle Ray

http://www.w3.org/2001/XMLSchema#string

Patrick McDaneld

http://www.w3.org/2001/XMLSchema#string

Peter L Anderson

http://www.w3.org/2001/XMLSchema#string

Samantha MaWhinney

http://www.w3.org/2001/XMLSchema#string

P2860

No influence of the P-glycoprotein polymorphisms MDR1 G2677T/A and C3435T on the virological and immunological response in treatment naïve HIV-positive patients

Genetic contribution to variable human CYP3A-mediated metabolism

Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1

A "silent" polymorphism in the MDR1 gene changes substrate specificity

A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function.

Dual protease inhibitor therapy in HIV-infected patients: pharmacologic rationale and clinical benefits.

Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance.

Atazanavir: new option for treatment of HIV infection.

Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients

ABCB1 pharmacogenetics: progress, pitfalls, and promise.

P304

1071-1079

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JAC/DKP317

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

64

http://www.w3.org/2001/XMLSchema#string

P577

2009-08-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26770062

http://www.w3.org/2001/XMLSchema#string

P698

19710077

http://www.w3.org/2001/XMLSchema#string

P932

2760462

http://www.w3.org/2001/XMLSchema#string